Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis.
The reconstitution of lymphocyte subsets after high-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT) was studied using two-color flow cytometry in 14 patients with acute leukemia (four AML and two ALL) and malignant lymphoma (six NHL and two HD). The CD3+HLA-DR+ lymphocytes (activated T cells) and CD8+ lymphocytes increased markedly by 4 weeks after PBSCT. Most of the increased CD8+ lymphocytes were CD11b-, S6F1+ cells and CD8+CD11b+ cells remained low throughout the follow-up period. The CD4+ lymphocytes remained below the normal range up to 34 weeks after PBSCT. The ratio of CD4+ to CD8+ lymphocytes (CD4/CD8 ratio) transiently increased and then decreased below 1.0 at 2 weeks after PBSCT. The CD19+ lymphocytes and the CD3-CD16+CD56+ lymphocytes returned to normal levels in the early period. The CD4+CD45RA+ lymphocytes (suppressor-inducer) decreased to below the normal range, while the CD4+CD45RO+ lymphocytes (helper-inducer) increased more rapidly than the CD4+CD45RA+ lymphocytes. This study shows that an immunosuppressed state exists after PBSCT as is seen after bone marrow transplantation (BMT) and that B cell reconstitution is more rapid in PBSCT than in BMT.
Ashihara
E
E
Second Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
Shimazaki
C
C
Yamagata
N
N
Hirata
T
T
Okawa
K
K
Oku
N
N
Goto
H
H
Inaba
T
T
Fujita
N
N
Nakagawa
M
M
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016913:Blood Component Transfusion; D002066:Busulfan / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016130:Immunophenotyping / Q000379:methods*; D007951:Leukemia, Myeloid / Q000097:blood* / Q000188:drug therapy / Q000628:therapy; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D016131:Lymphocyte Subsets; D008223:Lymphoma / Q000097:blood* / Q000188:drug therapy / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010976:Platelet Count; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000188:drug therapy / Q000628:therapy
D009607:Nitrosourea Compounds; D005047:Etoposide; D002066:Busulfan; C020766:ranimustine